Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021
Recruiting · NCT07302607 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Strasbourg, France
View the official record on ClinicalTrials.gov →What this trial is about
Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥ 18 years;
- Unresectable stage III or stage IV melanoma according to the AJCC classification - 8th edition;
- Curative immunotherapy treatment (anti-PD-1 and/or anti-CTLA-4);
- Treatment and follow-up at the Dermatology Department of the Strasbourg University Hospitals;
- Immunotherapy initiated between January 1, 2013, and December 31, 2021.
Exclusion criteria
- Primary choroidal melanoma;
- Adjuvant-intent immunotherapy;
- Less than 3 months of follow-up after the start of immunotherapy;
- Change of treatment before the first reassessment;
- Treatment and follow-up at a department other than the Dermatology Department of the Strasbourg University Hospitals.
Where it is running
1 location listed.
- Service de dermatologie - Réanimation - CHU de Strasbourg - France - Strasbourg, France